Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab effects on synovial biomarkers in rheumatoid arthritis
NL-OMON36162Phase 4Withdrawn
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Amsterdam University Medical Center. Primary endpoint: Change in synovial CD68-positive macrophages. Planned start Apr 2011; status: withdrawn.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON36162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36162.